von Willebrand factor: A marker of endothelial dysfunction in vascular disorders?

Cardiovascular Research

Volumn 34, Issue 2, 1997, Pages 255-265

  Lip, Gregory Y H ^a   Blann, Andrew ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

Atherogenesis; Endothelium; Thrombogenesis; von Willebrand factor (vWf)

Indexed keywords

ANTICOAGULANT AGENT; HOMOCYSTEINE; VON WILLEBRAND FACTOR;

ATHEROSCLEROSIS; CEREBROVASCULAR DISEASE; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DISEASE COURSE; DISEASE MARKER; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE ANEURYSM; HOMOCYSTEINE URINE LEVEL; HUMAN; HYPERTENSION; INBORN ERROR OF METABOLISM; INFLAMMATORY DISEASE; ISCHEMIC HEART DISEASE; LUNG BLOOD VESSEL; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; REVIEW; RISK FACTOR; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOGENESIS; VASCULAR DISEASE; VASCULAR ENDOTHELIUM; VEIN THROMBOSIS;

ARTERIOSCLEROSIS; BIOLOGICAL MARKERS; DIABETES MELLITUS; ENDOTHELIUM, VASCULAR; HUMANS; HYPERTENSION; THROMBOSIS; VASCULAR DISEASES; VON WILLEBRAND FACTOR;

EID: 0030915655     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(97)00039-4     Document Type: Review

References (119)

1. Virchow R. Gesammelte Abhandlungen zur wissenschaftlichen Medizin. Frankfurt: Medinger Sohn and Co., 1856:219-732.
2. Badimon L, Badimon JJ, Fuster V. Pathogenesis of thrombosis. In: Fuster V, Verstraete M, editors. Thrombosis in cardiovascular disorders. Philadelphia: WB Saunders, 1992;17-39.
3. Boneu B, Abbal M, Plante J, Bierme R. Factor VIII complex and endothelial damage. Lancet 1975;i:1430.
4. Blann AD. von Willebrand factor and the endothelium in vascular disease. Br J Biomed Sci 1993;50:125-134.
5. Hamstein A. The hemostatic system and coronary heart disease. Thromb Res 1993;70:1-38.
6. Pottinger BE, Read RC, Paleolog EM, Higgins PG, Pearson JD. von Willebrand factor is an acute phase reactant in man. Thromb Res 1989;53:387-394.
7. Hekman CM, Loskutoff DJ. Fibrinolytic pathways and the endothelium. Sem Thromb Haemost 1987;13:514-527.
8. Nordoy A. Haemostatic factors in coronary heart disease. J Intern Med 1993;233:377-383.
9. Ruggeri ZM, Ware J, Ginsberg D. von Willebrand factor. In: Loscalzo J, Schafer AI, editors. Thrombosis and Hemorrhage. Boston: Blackwell, 1994;305-329.
10. Over J, Sixma JJ, Doucet de Bruine MH, et al. Survival of 125-iodine labelled factor VIII in normals and patients with classical hemophilia. Observations on the heterogeneity of human factor VIII. J Clin Invest 1978;62:223-234.
11. Wagner DD. Cell biology of von Willebrand factor. Annu Rev Cell Biol 1990;6:217-246.
12. Sporn LA, Marder VJ, Wagner DD. Inducible secretion of large, biologically potent vWf multimers. Cell 1986;46:185-190.
13. Blann AD, Taberner DA. A reliable marker of endothelial cell dysfunction: Does it exist? Br J Haematol 1995;90:244-248.
14. Pearson JD. Markers of endothelial cell perturbation and damage. Br J Rheumatol 1993;32:651-652.
15. Ginsburg D, Sadler JE. von Willebrand disease: a database of point mutations, insertions and deletions. Thromb Haemost 1993;69:177-184.
16. Nichols TC, Bellinger DA, Tate DA, et al. von Willebrand factor and occlusive arterial thrombosis: a study in normal and von Willebrand's disease pigs with diet-induced hypercholesterolaemia and atherosclerosis. Atherosclerosis 1990;10:449-461.
17. Bowie EJW. The role of von Willebrand factor in thrombosis. In: Poller L, Thomson JM, editors. Thrombosis and its management. Edinburgh: Churchill Livingstone, 1993;134-140.
18. Rosendaal FR, Briet E, Stibb J, et al. Haemophilia protects against ischaemic heart disease: a story of risk factors. Br J Haematol 1990;75:525-530.
19. Ware RE, Parker RI, McKeown LP, Graham ML. A human chimaera for von Willebrand disease following bone marrow transplantation. Am J Pediatr Hematol Oncol 1993;15:388-392.
20. Weiss HJ, Hawiger J, Ruggeri ZM, Turitto VT, Thiagarajan P, Hoffmann T. Fibrinogen-independent platelet adhesion and thrombus formation on subendothelium mediated by glycoprotein IIb-IIIa complex at high shear rate. J Clin Invest 1989;83:288-297.
21. 3) mediated by fibrinogen and glycoprotein Ib-von Willebrand factor. J Biol Chem 1992;267:11300-11306.
22. Gralnick HR, Williams SB, Morisato DK. Effect of the multimeric structure of the factor VIII/von Willebrand factor protein on binding to platelets. Blood 1981;58:387-397.
23. Topol EJ, Califf RM, Weisman HF, et al. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet 1994;343:881-886.
24. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIa receptors in cardiovascular medicine. N Engl J Med 1995;332:1553-1559.
25. Bellucci S, Ignatova E, Jaillet N, Boffa MC. Platelet hyperactivation in patients with essential thrombocythemia is not associated with vascular endothelial cell damage as judged by the levels of plasma thrombomodulin, protein S, PAI-1, tPA and vWf. Thromb Haemost 1993;70:736-742.
26. Green D, Kucuk O, Haring O, Dyer A. The factor VIII complex in atherosclerosis: effects of aspirin. J Chronic Dis 1981;34:21-26.
27. Hamsten A, Blomback M, Wiman B, et al. Haemostatic function in myocardial infarction. Br Heart J 1986;55:58-66.
28. Haines AP, Howarth D, North WRS, et al. Haemostatic variables and the outcome of myocardial infarction. Thromb Haemost 1983;50:800-803.
29. Lip GYH, Lowe GDO, Metcalfe MJ, Rumley A, Dunn FG. Effects of warfarin therapy on plasma fibrinogen, von Willebrand factor and fibrin D-dimer in left ventricular dysfunction secondary to coronary artery disease with and without aneurysms. Am J Cardiol 1995;76:453-458.
30. Schmitz-Huebner U, Thompson SG, Balleisen L, et al. Lack of association between haemostatic variables and the presence or the extent of coronary atherosclerosis. Br Heart J 1988;59:287-291.
31. Moisseev SI. The role of hemostasis and rheologic properties of blood in stable and progressive exertion-induced sternocardia. Kardiologiia 1988;28:67-71[in Russian].
32. Bridges AB, McLaren M, Scott NA, Pringle TH, McNeill GP, Belch JJ. Circadian variation of tissue plasminogen activator and its inhibitor, von Willebrand factor antigen, and prostacyclin stimulating factor in men with ischaemic haert disease. Br Heart J 1993;69:121-124.
33. Bridges AB, McAlpine HM, Pringle TH, McLaren M, Belch JJF. Endothelial dysfunction in acute myocardial infarction. Am Heart J 1993;126:451-452.
34. Giustolisi R, Musso R, Cacciola E, Cacciola RR, Russo M, Petralito A. Abnormal plasma levels of factor VIII/ von Willebrand factor complex in myocardial infarction - Expression of acute phase reaction or index of vascular endothelium damage? Thromb Haemostat 1984;51:408.
35. Davies SW, Ranjadayalan K, Wickens DG, Dormandy TL, Timmis AD. Lipid peroxidation associated with successful thrombolysis. Lancet 1990;335:741-743.
36. Andreotti F, Hackett DR, Haider AW, et al. von Willebrand factor, plasminogen activator inhibitor-1 and C-reactive protein are markers of thrombolytic efficacy in acute myocardial infarction. Thromb Haemostat 1992;68:678-682.
37. Andreotti F, Roncaglioni C, Hackett DR, Khan MI, Regan T, Haider AW, et al. Early coronary reperfusion blunts the procoagulant response of plasminogen activator inhibitor-1 and von Willebrand factor in acute myocardial infarction. J Am Coll Cardiol 1990;16:1553-1560.
38. Blann A, Midgley H, Burrows G, et al. Free radicals, antioxidants and endothelial cell damage after percutaneous transluminal coronary angioplasty. Coron Artery Dis 1993;4:905-910.
39. Jansson JH, Nilsson TK, Johnson O. von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death. Br Heart J 1991;66:351-355.
40. Cortellaro M, Boschetti C, Cofrancesco E, et al. The PLAT study: hemostatic function in relation to atherothrombotic ischemic events in vascular disease patients. Arterioscler Thromb 1992;12:1063-1070.
41. Thompson SG, Kienast J, Pyke SDM, Haverkate F, van der Loo JCW. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995;332:635-641.
42. Meade TW, Cooper JA, Stirling Y, Howarth DJ, Ruddock V, Miller GJ. Factor VIII, ABO blood group and the incidence of ischaemic heart disease. Br J Haematol 1994:88;601-607.
43. Meade TW, Mellows S, Brozovic M, et al. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park heart study. Lancet 1986;2:533-537.
44. Hamsten A, Wiman B, De Faire U, Blombäck M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985;313:1557-1563.
45. Montalescot G, Ankri A, Vicaut E, Drobinski G, Grosgogeat Y, Thomas D. Fibrinogen after coronary angioplasty as a risk factor for restenosis. Circulation 1995;92:31-38.
46. Smith FB, Lowe GDO, Fowkes FG, et al. Smoking, hemostatic factors and lipid peroxides in a population case-control study of peripheral arterial disease. Atherosclerosis 1993;102:155-162.
47. Woodburn KF, Rumley A, Pollock JG, Quin RO, Lowe GD. Prediction of outcome in infrainguinal bypass grafting. Br J Surg 1993;80:525-526.
48. Woodburn KR, Rumley A, Lowe GDO, Pollock JG. Fibrinogen and markers of fibrinolysis and endothelial damage following resolution of critical limb ischaemia. Eur J Vase Endovasc Surg 1995;10:272-278.
49. Woodburn KR, Lowe GDO, Rumley A, Love J, Pollock JG. Relation of haemostatic, fibrinolytic and rheological variables to the angiographic extent of peripheral arterial occlusive disease. Int Angiol 1995;14:346-352.
50. Fowkes FGR, Lowe GDO, Housley E, et al. Cross linked fibrin degradation products, progression of peripheral arterial disease, and risk of coronary artery disease. Lancet 1993;342:84-86.
51. Edwards AT, Blann AD, Suarez-Mendez VJ, Lardi AM, McCollum CN. Systemic responses in patients with intermittent claudication after treadmill exercise. Br J Surg 1994;81:1738-1741.
52. Blann AD, Maxwell SRJ, Burrows G, Miller JP. Antioxidants, von Willebrand factor and endothelial cell damage in hypercholesterolaemia and vascular disease. Atherosclerosis 1995;116:191-198.
53. Blann AD, Seigneur M, Adams R, McCollum CN. Neutrophil elastase, von Willebrand factor, soluble thrombomodulin and percutaneous exygen in peripheral atherosclerosis. Eur J Vase Endovasc Surg 1996;12:218-222.
54. Lip GYH. Does atrial fibrillation confer a hypercoagulable state? Lancet 1995;346:1313-1314.
55. Lip GYH, Lowe GDO, Rumley A, Dunn FG. Increased markers of thrombogenesis in chronic atrial fibrillation: Effects of warfarin therapy. Br Heart J 1995;73:527-533.
56. Yamamoto K, Ikeda U, Seino Y, et al. Coagulation activity is increased in the left atrium of patients with mitral stenosis. J Am Coll Cardiol 1995;25:107-112.
57. Lip GYH. Intracardiac thrombus formation in cardiac impairment: Investigation and the role of anticoagulant therapy. Postgrad Med J 1996;72:731-738.
58. Lip GYH, Zarifis J. Diastolic dysfunction: a review. Eur J Intern Med 1995;6:145-154.
59. Lip GYH, Lowe GDO, Metcalfe MJ, Rumley A, Dunn FG. Is diastolic dysfunction associated with thrombogenesis? A study of circulating markers of a prothrombotic state in patients with coronary artery disease. Int J Cardiol 1995;50:31-42.
60. Mettinger KL. A study of hemostasis in ischemic cerebrovascular disease. I. Abnormalities in factor VIII and antithrombin. Thromb Res 1982;26:183-192.
61. Uchiyama S, Takeuchi M, Osawa M, et al. Platelet function tests in thrombotic cerebrovascular disorders. Stroke 1983;14:511-517.
62. Wahlberg T, Blomback M, Overmark I. Blood coagulation studies in 45 patients with ischemic cerebrovascular disease and 44 patients with venous thromboembolic disease. Acta Med Scand 1980;207:385-390.
63. Liu L, Lin Z, Shen S. Changes of von Willebrand factor and antithrombin III levels in acute stroke: Differences between thrombotic and haemorrhagic stroke. Thromb Res 1993;72:353-358.
64. Zarifis J, Blann AD, Farooqi IS, Sagar G, Beevers DG, Lip GYH. Increased soluble adhesion molecule P-selectin, von Willebrand factor and fibrinogen in acute stroke: evidence for early endothelial and haemorheological dysfunction. Clin Sci 1996;Suppl 34:27P.
65. Nilsson T, Mellbring G, Hedner U. Relationship between factor XII, von Wilebrand factor and postoperative deep venous thrombosis. Acta Chir Scand 1986;152:347-349.
66. Koster T, Blann AD, Briet E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurence of deep vein thrombosis. Lancet 1995:345;152-155.
67. Penny WF, Weinstein M, Salzman EW, Ware JA. Correlation of circulating von Willebrand factor levels with cardiovascular hemodynamics. Circulation 1991;83:1630-166.
68. Geggel RL, Carvalho AC, Hoyer LW, Reid LM. von Willebrand factor abnormalities in primary pulmonary hypertension. Am Rev Respir Dis 1987;135:294-299.
69. Collier A, Rumley A, Rumley AG, et al. Free radical activity and hemostatic factors in NIDDM patients with and without microalbuminuria. Diabetes 1992;41:909-913.
70. Greaves M, Pickering C, Knoght G, et al. Changes in factor VIII complex in diabetic ketoacidosis: evidence of endothelial cell damage? Diabetologia 1987:30;160-165.
71. Stehouwer CDA, Nauta JJP, Zeldenrust GC, Hackeng WHL, Donker AJM, den Ottolander GJH. Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in non-insulin dependent diabetes mellitus. Lancet 1992;340:319-323.
72. Kohriyama T, Katayama S, Tanaka E, Yamamura Y, Nakamura S. Coagulation and fibrinolytic parameters in pateints with various angiopathies - analysis in cerebral thrombosis, diabetic and vasculitic neuropathies. Rinsho Shinkeigaku - Clin Neurol 1993;33:606-611[in Japanese].
73. Nilsson TK, Boman K, Bjerle P, Hallmans G, Hellsten G. von Willebrand factor and fibrinolytic variables are differently affected in the insulin resistance syndrome. J Intern Med 1994;235:419-423.
74. Steiner M, Reinhardt KM, Krammer B, Ernst B, Blann AD. Increased levels of soluble adhesion molecules in type 2 (non-insulin dependent) diabetes mellitus are independent of glycaemic control. Thromb Haemost 1994:72;979-984.
75. Davies MG. The vascular endothelium. A new horizon. Ann Surg 1993;218:593-609.
76. Lip GYH, Beevers DG. Abnormalities of rheology and coagulation in hypertension. J Hum Hypertens 1994;8:693-702.
77. Blann AD, Naqvi T, Waite M, McCollum CN. von Willebrand factor and endothelial damage in essential hypertension. J Hum Hypertens 1993;7:107-111.
78. Lip GYH, Blann AD, Zarifis J, Beevers M, Lip PL, Beevers DG. Soluble adhesion molecule P-selectin and endothelial dysfunction in essential hypertension: implications for atherogenesis. A preliminary report. J Hypertens 1995;13:1674-1678.
79. Varizi ND, Smith DH, Winer RL, Weber MA, Gonzales EC, Meutel JM. Coagulation and inhibitory and fibrinolytic proteins in essential hypertension. J Am Soc Nephrol 1993;4:222-228.
80. Pedrinelli R, Giampietro O, Carmassi F, et al. Microalbuminuria and endothelial dysfunction in essential hypertension. Lancet 1994;344:14-18.
81. Brenner B, Zwang E, Bronshtein M, Seligsohn U. von Willebrand factor multimer patterns in pregnancy-induced hypertension. Thromb Haemost 1989;62:715-717.
82. Deng L, Bremme K, Hansson LO, Blomback M. Plasma levels of von Willebrand factor and fibronectin as markers of persisting endothelial damage in preeclampsia. Obstet Gynecol 1994:84;941-945.
83. Luscher TF. The endothelium: Target or promoter of hypertension? Hypertension 1990;15:482-485.
84. Blann AD, Hopkins J, Winkles J, Wainwright AC. Plasma and serum von Willebrand factor antigen concentrations in connective tissue disorders. Ann Clin Biochem 1992;29:67-71.
85. Lau CS, McLaren M, Mackay I, Belch JJ. Baseline plasma fibrinolysis and its correlation with clinical manifestation in patients with Raynaud's phenomenon. Ann Rheum Dis 1993;52:443-448.
86. Blann AD, Illingworth K, Jayson MI. Mechanisms of endothelial cell damage in systemic sclerosis and Raynaud's phenomenon. J Rheumatol 1993;20:1325-1330.
87. Wallberg-Jonsson S, Dahlen GH, Nilsson TK, Ranby M, Rantapaa-Dahlqvist S. Tissue plasminogen activator, plasminogen activator inhibitor and von Willebrand factor in rheumatoid arthritis. Clin Rheum 1993:12;318-324.
88. Blann AD, Sheeran TP, Emery P. von Willebrand factor: increased levels are related to poor prognosis in systemic sclerosis and not to tissue autoantibodies. Br J Biomed Sci 1997;54:in press.
89. Bryon MA, Allington MJ, Chapel HM, Mowat AG, Cederholm-Williams SA. Indications of vascular endothelial cell dysfunction in systemic lupus erythematosus. Ann Rheum Dis 1987;46:741-745.
90. Matsuda J, Tsukamoto M, Gohchi K, Saitoh N, Miyajima Y, Kazama M. Effect of total body cold exposure on plasma concentrations of vWf, endothelin-1 and thrombomodulin in SLE with or without Raynaud's phenomenon. Acta Haematol 1992;88:189-193.
91. Lindsey NJ, Dawson RA, Henderson FI, Greaves M, Hughes P. Stimulation of von Willebrand factor antigen release by immunoglobulin from thrombosis prone patients with systemic lupus erythematosus and the anti-phospholipid syndrome. Br J Rheumatol 1993;32:123-126.
92. Rosenbaum J, Pottinger BE, Woo P, et al. Measurement and characterisation of circulating antiendothelial cell IgG in connective tissue diseases. Clin Exp Immunol 1988;72:450-456.
93. Hasselar P, Derksen RHWM, Bloksijl L, de Groot PG. Cross-reactivity of antibodies directed against cardiolipin, DNA, endothelial cells and blood platelets. Thromb Haemost 1990;63:169-173.
94. Cines DB, Lyss AP, Reeber M, Bina M, deHoratius RJ. Presence of complement-fixing antibodies in systemic lupus erythematosus. J Clin Invest 1984;73:611-625.
95. Penning CA, Fench MAH, Rowell NR, Hughes P. Antibody-dependent cellular cytotoxicity of human endothelium in systemic lupus erythematosus. J Clin Lab Immunol 1985;17:125-130.
96. Watson KV, Schorer AE. Lupus anticoagulant inhibition of in-vitro prostacyclin release is associated with a thrombosis-prone subset of patients. Am J Med 1991;90:47-53.
97. Lindsey N, Henderson F, Malia R, Greaves M, Hughes P. Serum masks the inhibition of thrombin-induced prostacyclin release produced by anticardiolipin antibodies. Br J Rheumatol 1992;31:179-183.
98. Rees MM, Rodgers GM. Homocysteinemia: association of a metabolic disorder with vascular disease and thrombosis. Thromb Res 1993:71;337-359.
99. Lenz SR, Sadler JE. Homocysteine inhibits von Willebrand factor processing and secretion by preventing transport from the endoplasmic reticulum. Blood 1993;81:683-689.
100. Dudman NPB, Hicks C, Wang J, Wilcken DEL. Human arterial endothelial cell detachment in vitro: its promotion by homocysteine and cysteine. Atherosclerosis 1991:91;77-83.
101. Blann AD. Endothelial cell damage and homocysteine. Atherosclerosis 1992:94;89-91.
102. Molgaard J, Malinow MR, Lassvik C, Holm AC, Upson B, Olsson AG. Hyperhomocyst(e)inaemia: an independent risk factor for intermittent claudication. J Int Med 1992:231;273-279.
103. Ruggeri ZM. von Willebrand factor as a target for antithrombotic intervention. Circulation 1992;86 Suppl III:III-26-III-29.
104. Blann AD. von Willebrand and atherosclerosis. J Intern Med 1995;237:432-433.
105. Blann AD, Jackson P, Bath PMW, Watts GF. von Willebrand factor, a possible indicator of endothelial cell damage, decreases during long-term compliance with a lipid-lowering diet. J Int Med 1995;237:557-561.
106. Witztum JL, Steinberg D. Role of oxidised low density lipoprotein in atherogenesis. J Clin Invest 1991;88:1785-1792.
107. Shahar E, Folsom AR, Wu KK, et al. Associations of fish intake and dietary n-3 polyunsaturated fatty acids with a hypercoagulable profile. Arterioscler Thromb 1993;13:1205-1212.
108. Riemersma RA, Wood DA, Butler S, et al. Linoleic acid content of adipose tissue and coronary heart disease. Br Med J 1986;292:1423-1427.
109. Blann AD, Davies A, Miller JP, McCollum CN. von Willebrand factor and soluble E-selectin in hyperlipidaemia: relationship to lipids and vascular disease. Am J Haem 1997;55:in press.
110. Blann AD, Bushell D, Davies A, Faragher EB, Miller JP, McCollum CN. von Willebrand factor, the endothelium and obesity. Int J Obesity 1993:17;723-725.
111. Sobel M, Bird KE, Tyler-Cross R, et al. Heparins designed to specifically inhibit platelet interactions with von Willebrand factor. Circulation 1996;93:992-999.
112. Dardik R, Ruggeri ZM, Savion N, Gitel S, Martinowitz U, Chu V, Varon D. Platelet aggregation on extracellular matrix: Effect of a recombinant GPIb-binding fragment of von Willebrand factor. Thromb Haemost 1993;70:522-526.
113. Phillips MD, Moake JL, Nolasco L, Turner N. Aurin tricardoxylic acid: a novel inhibitor of the association of von Willebrand factor and platelets. Blood 1988;72:1898-1903.
114. Stuart J, George AJ, Davies AJ, et al. Haematological stress syndrome in atherosclerosis. J Clin Pathol 1981;34:464-467.
115. Uchiyama T, Matsumoto M, Kobayashi N. Studies on the pathogenesis of coagulopathy in patients with arterial thromboembolism and malignancy. Thromb Res 1990;59:955-965.
116. Blann AD. von Willebrand factor as a marker of injury to the endothelium in infalmmatory vascular disease. J Rheumatol 1993;20:1469-1471.
117. Pober JS. Cytokine mediated activation of vascular endothelium. Am J Pathol 1988;133:426-433.
118. Pearson JD. Vessel wall interactions regulating thrombosis. Br Med Bull 1995;50:776-788.
119. Blann AD, Steele C, McCollum CN. The influence of smoking on soluble adhesion molecules and endothelial cell markers. Thromb Res 1997;in press.